Trials / Unknown
UnknownNCT03655353
A Study of 68Ga-ABY-025 PET for Non-invasive Quantification of HER2-expression in Advanced Breast Cancer
A Multicenter Phase II/III-study of 68Ga-ABY-025 PET for Non-invasive Quantification of HER2-expression in Advanced Breast Cancer
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 160 (estimated)
- Sponsor
- Henrik Lindman · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A large multi- center phase II/III study with 68Ga-ABY-025 PET and biopsies in patients with advanced HER2-positive breast cancer, where the primary endpoint of the study is to find out the correlation between the HER2 expression measured by 68Ga-ABY-025 PET and standard histopathology from relevant tumor biopsies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | ABY-PET | Diagnostic PET for HER2 expression |
Timeline
- Start date
- 2018-08-22
- Primary completion
- 2024-11-01
- Completion
- 2025-11-01
- First posted
- 2018-08-31
- Last updated
- 2021-09-29
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT03655353. Inclusion in this directory is not an endorsement.